Webinar Technology

Best practices in transfection: Impacts on gene editing, virus production, and more

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Best practices in transfection: Impacts on gene editing, virus production, and more

25 January 2018

12:00 p.m. ET

Register now!

Speakers

Transfection of cells in culture is a key technique in the molecular and cell biology toolbox. Toxicity and efficiency are the factors that have the biggest impact on the success of transfection experiments and can significantly affect important downstream applications. In this webinar, we discuss the key steps and protocol considerations for performing high-quality transfections on a consistent basis, taking into consideration variables such as cell type, culture conditions, reagent concentrations, and other critical parameters. Drawing attention to these factors will ultimately lead to better downstream results for gene expression and other emerging applications, such as CRISPR/Cas9 genome editing, virus production, and cell-line development for biotherapeutic protein production. During the webinar, the speakers will:

During the webinar, the speakers will:

  • Introduce the most critical factors to consider in any transfection experiment
  • Discuss optimization procedures for a range of transfection applications, including recombinant protein production, CRISPR-based gene editing, and virus production
  • Highlight current trends and new applications in transfection
  • Answer your questions live during the broadcast!

This webinar will last for approximately 60 minutes.

Speaker bios

Patrick Sinn, Ph.D.

University of Iowa
Iowa City, IA

Dr. Sinn is a research associate professor in the Department of Pediatrics, Division of Allergy, Immunology, and Pulmonary Disease, Carver College of Medicine at the University of Iowa. His laboratory is part of the university’s multidisciplinary Lung Biology and Cystic Fibrosis Research Center. Dr. Sinn directs the university’s Viral Vector Core, a facility designed for viral vector production and worldwide distribution. His laboratory focuses on improving viral vector design, delivery efficiency, and vector safety for gene transfer applications.

Le Cong, Ph.D.

Broad Institute of MIT and Harvard
Cambridge, MA

Dr. Cong obtained his B.S. with highest honors from Tsinghua University in Beijing, and his Ph.D. from Harvard Medical School. He completed doctoral work primarily in the laboratory of Dr. Feng Zhang, where he published a seminal study in Science demonstrating the application of CRISPR/Cas9 for genome editing—this article remains one of the most highly cited papers in the CRISPR field. He has obtained over 14 U.S. and European Union patents, and subsequently modified the CRISPR system for gene and cell therapy. He is currently working to apply single-cell genomics and genome engineering for cancer immunotherapy under Dr. Aviv Regev at the Broad Institute of MIT and Harvard, and will soon be starting his own independent group. Dr. Cong was a Howard Hughes Medical Institute International Student Research Fellow, a Cancer Research Institute Irvington Postdoctoral Fellow, and was included in the Forbes 30 Under 30 Asia/China list of young innovators and entrepreneurs.

Ally Hauser, M.S., and Katie Rogers, B.S.

Aldevron
Madison, WI

Ms. Hauser is client relations manager for Protein Services at Aldevron in Madison, Wisconsin. She received her Master’s in biology from Case Western Reserve University; over the course of her 18-year career, she has focused on providing technical expertise to protein expression clients. She works with Aldevron clients to help them understand the primary goal for a protein production project, presenting options and facilitating conversations on best practices and risk management in mammalian, E. coli, and insect-cell recombinant protein platforms. She also serves as a client resource, connecting clients with internal and external scientific resources to advance their plasmid, messenger RNA, and antibody discovery programs.

Ms. Rogers has practiced the art and science of mammalian cell tissue culture for almost 30 years. She has led product development for Novagen and EMD Biosciences (now EMD Millipore) in the areas of transfection reagents and expression vectors. As a senior scientist at Aldevron, she develops protocols for optimizing and scaling-up mammalian protein expression from milligrams to grams, or from 30-mL to 25-L culture scales. She also leads Aldevron’s molecular biology program and protein expression services in systems including E. coli, insect cells, and mammalian cells.

Sean Sanders, Ph.D.

Science/AAAS
Washington, DC

Dr. Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Senior Editor for Custom Publishing for the journal Science and Program Director for Outreach.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here